Remdesivir Market Size and Outlook 2031

Report Description

Forecast Period	2027-2031
Market Size (2025)	USD 4.92 Billion
CAGR (2026-2031)	6.23%
Fastest Growing Segment	Intravenous
Largest Market	North America
Market Size (2031)	USD 7.07 Billion

Market Overview

The Global Remdesivir Market is projected to grow from USD 4.92 Billion in 2025 to USD 7.07 Billion by 2031 at a 6.23% CAGR. Remdesivir, marketed as Veklury, is a broad-spectrum antiviral nucleoside analog prodrug developed by Gilead Sciences that inhibits viral RNA-dependent RNA polymerase, thereby disrupting viral replication. The global Remdesivir market experiences growth primarily driven by the ongoing need for effective antiviral therapies to combat respiratory and other viral infections, coupled with robust government support and funding for antiviral development and treatment initiatives. Advancements in pharmaceutical research also contribute by enhancing drug efficacy and expanding therapeutic applications.

A significant challenge impeding market expansion is the waning demand for COVID-19-specific antiviral treatments as the incidence of severe cases and associated hospitalizations has decreased. Furthermore, emerging drug resistance and the substantial costs associated with pharmaceutical development present ongoing hurdles. According to the American Medical Association, a US-based professional organization, US health spending increased by 7.5% in 2023, reaching $4.9 trillion, which indirectly supports the broader pharmaceutical market, including antivirals.

Key Market Drivers

Persistent global viral disease burden remains a primary catalyst for the Remdesivir market. The continuous emergence and circulation of diverse respiratory viruses, including new variants of SARS-CoV-2 and seasonal influenza, necessitate readily available and effective antiviral treatments. These pathogens impose significant pressure on healthcare systems worldwide, driving the demand for therapies that can mitigate severe outcomes and reduce hospitalization rates. According to the Centers for Disease Control and Prevention, in February 2026, an estimated 290,000 to 450,000 COVID-19 associated hospitalizations occurred in the United States between October 1, 2024, and July 5, 2025. This ongoing burden underscores the critical need for antivirals like Remdesivir to manage acute viral infections and prevent disease progression.

Strong government support and pandemic preparedness initiatives also significantly propel the global Remdesivir market. Governments worldwide are increasingly investing in developing and stockpiling antiviral countermeasures, enhancing their response capabilities to future health crises. This commitment ensures funding for research, development, and procurement of essential medicines. In February 2026, the Biomedical Advanced Research and Development Authority (BARDA) launched the Small Molecule Approaches for Rapid and Robust Treatment (SMART) Antiviral Prize, a $100 million competition to accelerate broad-spectrum antiviral development. This reflects sustained governmental focus on innovative antiviral therapies. Concurrently, the broader pharmaceutical market's investment landscape also influences antiviral development and availability, with Johnson & Johnson reporting a reduction in R&D spending by approximately 15% to $14.665 billion in 2025, as noted in March 2026. These combined efforts underline a robust environment for antiviral market evolution.

Download Free Sample Report

Key Market Challenges

A significant challenge impeding the growth of the global Remdesivir market is the diminishing demand for COVID-19-specific antiviral treatments. As the global incidence of severe COVID-19 cases and associated hospitalizations continues to decrease, the critical need for immediate therapeutic interventions such as Remdesivir (Veklury) has substantially lessened. This reduction directly translates into lower utilization and procurement of the drug by healthcare systems worldwide.

The direct impact of this declining demand is evident in the market performance of Remdesivir. According to Gilead Sciences, the developer of Veklury, full-year 2025 Veklury revenue was $911 million, representing a 49% decrease from its 2024 sales. This substantial decline was primarily driven by lower rates of COVID-19-related hospitalizations. This trend highlights how the evolving epidemiological landscape of COVID-19 directly undermines the market potential for treatments primarily linked to severe manifestations of the virus.

Key Market Trends

The global Remdesivir market is significantly influenced by the evolving post-patent landscape and increasing biosimilar competition. Although core compound patents for Veklury extend into the mid-2030s, the current period is characterized by intensified patent challenges and the expiration of certain regional exclusivities. This dynamic prompts original manufacturers to rigorously defend their intellectual property, while generic manufacturers actively explore market entry. Such competitive pressure could lead to the introduction of lower-cost alternatives, potentially affecting Remdesivir's pricing and market share in various jurisdictions. According to JUVE Patent, in August 2025, Gilead Sciences filed a revocation action at the Milan section of the Central Division against a patent held by the Chinese Academy of Military Medical Sciences, highlighting ongoing efforts to shape the intellectual property terrain.

Another critical trend shaping the Remdesivir market is the emergence of combination therapies, integrating Remdesivir with other antiviral agents or repurposed drugs. This strategy aims to enhance efficacy, broaden viral coverage, or improve patient outcomes, stemming from the complex nature of viral infections and the potential for synergistic effects to overcome resistance. These advancements seek to expand Remdesivir's utility beyond initial indications, securing its relevance in evolving treatment paradigms. A study published in J Infect Chemother on August 29, 2025, reported that combination therapy involving Remdesivir alongside nirmatrelvir/ritonavir or ensitrelvir proved effective in 12 out of 13 cases (92%) as a first-line treatment for COVID-19 patients with hematological malignancies.

Segmental Insights

The Intravenous segment stands out as the fastest-growing within the Global Remdesivir Market, primarily due to Remdesivir's inherent formulation and its crucial role in treating COVID-19. Remdesivir, marketed as Veklury, is administered as an intravenous infusion to ensure effective systemic drug exposure necessary to inhibit viral replication. Regulatory bodies, such as the U.S. Food and Drug Administration (FDA), have approved and authorized its emergency use for hospitalized patients and those at high risk for severe COVID-19, significantly driving demand for this administration route. This method facilitates direct delivery of the antiviral, which is vital in acute care and hospital settings where the drug has consistently demonstrated benefits in shortening recovery times and reducing hospitalization risk.

Regional Insights

North America leads the Global Remdesivir Market due to its robust healthcare infrastructure and proactive adoption of novel antiviral therapies. The region's dominance is significantly driven by strong government initiatives that supported large-scale procurement and widespread usage in hospitals and critical care units during the pandemic. Regulatory bodies such as the U.S. Food and Drug Administration (FDA) played a crucial role through early approvals for Remdesivir (Veklury), further accelerating its integration into treatment protocols across the healthcare system. This combination of advanced medical facilities, governmental support, and streamlined regulatory processes ensured broad accessibility and deployment of the drug.

Recent Developments

In October 2025, Gilead Sciences presented significant new research data regarding Veklury (remdesivir) at IDWeek 2025. The breakthrough involved new analyses from the Phase 3 REDPINE study, which focused on viral load dynamics in hospitalized COVID-19 patients. Specifically, the study evaluated individuals with severely impaired renal function or those who had undergone solid organ transplantation, two high-risk populations. These findings provided further insights into remdesivir's efficacy and clinical utility for vulnerable patients within the global remdesivir market.
In October 2025, Gilead Sciences announced a donation of 1,100 vials of remdesivir to support a clinical trial for Ebola disease in the Democratic Republic of the Congo. This initiative was a collaborative effort with the World Health Organization and the DRC government, aiming to investigate remdesivir's potential in treating Ebola. The donation highlighted Gilead's ongoing commitment to global public health challenges and demonstrated the company's efforts to explore the broader antiviral applications of remdesivir, extending its relevance beyond the COVID-19 market.
In August 2025, Gilead Sciences initiated a patent revocation action with the Unified Patent Court, targeting a patent held by the Chinese Academy of Military Medical Sciences. This patent concerned the use of specific compounds in SARS-CoV-2 treatment, which could potentially disrupt sales of remdesivir, marketed as Veklury. Gilead's legal offensive, which also included an opposition filed with the European Patent Office, aimed to safeguard its commercial interests and market position for its antiviral therapy in the European region. This action was a direct measure to protect the global remdesivir market.
In July 2025, published research revealed a significant finding concerning remdesivir's impact on long-term COVID-19 outcomes. A retrospective cohort study concluded that exposure to remdesivir during the acute phase of COVID-19 was associated with a lower risk of developing Long COVID. This extensive study, which included over 52,000 hospitalized patients, indicated that individuals who received remdesivir experienced a reduced risk for both overall and several specific Long COVID conditions, thereby emphasizing the drug's potential for extended patient benefits.

Key Market Players

Gilead Sciences, Inc.
Cipla Limited
Dr. Reddy’s Laboratories Limited
Hetero Labs Limited
Mylan N.V.
Sun Pharmaceutical Industries Limited
Zydus Lifesciences Limited
Jubilant Pharmova Limited
Aurobindo Pharma Limited
Fujifilm Toyama Chemical Co., Ltd.

By Dosage Form	By Route of Administration	By Patient Age	By Application	By Distribution Channel	By Region
Lyophilized Solution Frozen Solution	Intravenous Inhalation	Geriatric Adult Pediatric	SARS-CoV-2 (COVID-19) MERS-CoV Ebola SARS-CoV	Hospitals Clinics Drug Stores Pharmacies	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Remdesivir Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Remdesivir Market, By Dosage Form:

Lyophilized Solution
Frozen Solution

Remdesivir Market, By Route of Administration:

Intravenous
Inhalation

Remdesivir Market, By Patient Age:

Geriatric
Adult
Pediatric

Remdesivir Market, By Application:

SARS-CoV-2 (COVID-19)
MERS-CoV
Ebola
SARS-CoV

Remdesivir Market, By Distribution Channel:

Hospitals
Clinics
Drug Stores
Pharmacies

Remdesivir Market, By Region:

North America

United States
Canada
Mexico

Europe

France
United Kingdom
Italy
Germany
Spain

Asia Pacific

China
India
Japan
Australia
South Korea

South America

Brazil
Argentina
Colombia

Middle East & Africa

South Africa
Saudi Arabia
UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Remdesivir Market.

Available Customizations:

Global Remdesivir Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Global Remdesivir Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1. Product Overview

1.1. Market Definition

1.2. Scope of the Market

1.2.1. Markets Covered

1.2.2. Years Considered for Study

1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study

2.2. Baseline Methodology

2.3. Key Industry Partners

2.4. Major Association and Secondary Sources

2.5. Forecasting Methodology

2.6. Data Triangulation & Validation

2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market

3.2. Overview of Key Market Segmentations

3.3. Overview of Key Market Players

3.4. Overview of Key Regions/Countries

3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Remdesivir Market Outlook

5.1. Market Size & Forecast

5.1.1. By Value

5.2. Market Share & Forecast

5.2.1. By Dosage Form (Lyophilized Solution, Frozen Solution)

5.2.2. By Route of Administration (Intravenous, Inhalation)

5.2.3. By Patient Age (Geriatric, Adult, Pediatric)

5.2.4. By Application (SARS-CoV-2 (COVID-19), MERS-CoV, Ebola, SARS-CoV)

5.2.5. By Distribution Channel (Hospitals, Clinics, Drug Stores, Pharmacies)

5.2.6. By Region

5.2.7. By Company (2025)

5.3. Market Map

6. North America Remdesivir Market Outlook

6.1. Market Size & Forecast

6.1.1. By Value

6.2. Market Share & Forecast

6.2.1. By Dosage Form

6.2.2. By Route of Administration

6.2.3. By Patient Age

6.2.4. By Application

6.2.5. By Distribution Channel

6.2.6. By Country

6.3. North America: Country Analysis

6.3.1. United States Remdesivir Market Outlook

6.3.1.1. Market Size & Forecast

6.3.1.1.1. By Value

6.3.1.2. Market Share & Forecast

6.3.1.2.1. By Dosage Form

6.3.1.2.2. By Route of Administration

6.3.1.2.3. By Patient Age

6.3.1.2.4. By Application

6.3.1.2.5. By Distribution Channel

6.3.2. Canada Remdesivir Market Outlook

6.3.2.1. Market Size & Forecast

6.3.2.1.1. By Value

6.3.2.2. Market Share & Forecast

6.3.2.2.1. By Dosage Form

6.3.2.2.2. By Route of Administration

6.3.2.2.3. By Patient Age

6.3.2.2.4. By Application

6.3.2.2.5. By Distribution Channel

6.3.3. Mexico Remdesivir Market Outlook

6.3.3.1. Market Size & Forecast

6.3.3.1.1. By Value

6.3.3.2. Market Share & Forecast

6.3.3.2.1. By Dosage Form

6.3.3.2.2. By Route of Administration

6.3.3.2.3. By Patient Age

6.3.3.2.4. By Application

6.3.3.2.5. By Distribution Channel

7. Europe Remdesivir Market Outlook

7.1. Market Size & Forecast

7.1.1. By Value

7.2. Market Share & Forecast

7.2.1. By Dosage Form

7.2.2. By Route of Administration

7.2.3. By Patient Age

7.2.4. By Application

7.2.5. By Distribution Channel

7.2.6. By Country

7.3. Europe: Country Analysis

7.3.1. Germany Remdesivir Market Outlook

7.3.1.1. Market Size & Forecast

7.3.1.1.1. By Value

7.3.1.2. Market Share & Forecast

7.3.1.2.1. By Dosage Form

7.3.1.2.2. By Route of Administration

7.3.1.2.3. By Patient Age

7.3.1.2.4. By Application

7.3.1.2.5. By Distribution Channel

7.3.2. France Remdesivir Market Outlook

7.3.2.1. Market Size & Forecast

7.3.2.1.1. By Value

7.3.2.2. Market Share & Forecast

7.3.2.2.1. By Dosage Form

7.3.2.2.2. By Route of Administration

7.3.2.2.3. By Patient Age

7.3.2.2.4. By Application

7.3.2.2.5. By Distribution Channel

7.3.3. United Kingdom Remdesivir Market Outlook

7.3.3.1. Market Size & Forecast

7.3.3.1.1. By Value

7.3.3.2. Market Share & Forecast

7.3.3.2.1. By Dosage Form

7.3.3.2.2. By Route of Administration

7.3.3.2.3. By Patient Age

7.3.3.2.4. By Application

7.3.3.2.5. By Distribution Channel

7.3.4. Italy Remdesivir Market Outlook

7.3.4.1. Market Size & Forecast

7.3.4.1.1. By Value

7.3.4.2. Market Share & Forecast

7.3.4.2.1. By Dosage Form

7.3.4.2.2. By Route of Administration

7.3.4.2.3. By Patient Age

7.3.4.2.4. By Application

7.3.4.2.5. By Distribution Channel

7.3.5. Spain Remdesivir Market Outlook

7.3.5.1. Market Size & Forecast

7.3.5.1.1. By Value

7.3.5.2. Market Share & Forecast

7.3.5.2.1. By Dosage Form

7.3.5.2.2. By Route of Administration

7.3.5.2.3. By Patient Age

7.3.5.2.4. By Application

7.3.5.2.5. By Distribution Channel

8. Asia Pacific Remdesivir Market Outlook

8.1. Market Size & Forecast

8.1.1. By Value

8.2. Market Share & Forecast

8.2.1. By Dosage Form

8.2.2. By Route of Administration

8.2.3. By Patient Age

8.2.4. By Application

8.2.5. By Distribution Channel

8.2.6. By Country

8.3. Asia Pacific: Country Analysis

8.3.1. China Remdesivir Market Outlook

8.3.1.1. Market Size & Forecast

8.3.1.1.1. By Value

8.3.1.2. Market Share & Forecast

8.3.1.2.1. By Dosage Form

8.3.1.2.2. By Route of Administration

8.3.1.2.3. By Patient Age

8.3.1.2.4. By Application

8.3.1.2.5. By Distribution Channel

8.3.2. India Remdesivir Market Outlook

8.3.2.1. Market Size & Forecast

8.3.2.1.1. By Value

8.3.2.2. Market Share & Forecast

8.3.2.2.1. By Dosage Form

8.3.2.2.2. By Route of Administration

8.3.2.2.3. By Patient Age

8.3.2.2.4. By Application

8.3.2.2.5. By Distribution Channel

8.3.3. Japan Remdesivir Market Outlook

8.3.3.1. Market Size & Forecast

8.3.3.1.1. By Value

8.3.3.2. Market Share & Forecast

8.3.3.2.1. By Dosage Form

8.3.3.2.2. By Route of Administration

8.3.3.2.3. By Patient Age

8.3.3.2.4. By Application

8.3.3.2.5. By Distribution Channel

8.3.4. South Korea Remdesivir Market Outlook

8.3.4.1. Market Size & Forecast

8.3.4.1.1. By Value

8.3.4.2. Market Share & Forecast

8.3.4.2.1. By Dosage Form

8.3.4.2.2. By Route of Administration

8.3.4.2.3. By Patient Age

8.3.4.2.4. By Application

8.3.4.2.5. By Distribution Channel

8.3.5. Australia Remdesivir Market Outlook

8.3.5.1. Market Size & Forecast

8.3.5.1.1. By Value

8.3.5.2. Market Share & Forecast

8.3.5.2.1. By Dosage Form

8.3.5.2.2. By Route of Administration

8.3.5.2.3. By Patient Age

8.3.5.2.4. By Application

8.3.5.2.5. By Distribution Channel

9. Middle East & Africa Remdesivir Market Outlook

9.1. Market Size & Forecast

9.1.1. By Value

9.2. Market Share & Forecast

9.2.1. By Dosage Form

9.2.2. By Route of Administration

9.2.3. By Patient Age

9.2.4. By Application

9.2.5. By Distribution Channel

9.2.6. By Country

9.3. Middle East & Africa: Country Analysis

9.3.1. Saudi Arabia Remdesivir Market Outlook

9.3.1.1. Market Size & Forecast

9.3.1.1.1. By Value

9.3.1.2. Market Share & Forecast

9.3.1.2.1. By Dosage Form

9.3.1.2.2. By Route of Administration

9.3.1.2.3. By Patient Age

9.3.1.2.4. By Application

9.3.1.2.5. By Distribution Channel

9.3.2. UAE Remdesivir Market Outlook

9.3.2.1. Market Size & Forecast

9.3.2.1.1. By Value

9.3.2.2. Market Share & Forecast

9.3.2.2.1. By Dosage Form

9.3.2.2.2. By Route of Administration

9.3.2.2.3. By Patient Age

9.3.2.2.4. By Application

9.3.2.2.5. By Distribution Channel

9.3.3. South Africa Remdesivir Market Outlook

9.3.3.1. Market Size & Forecast

9.3.3.1.1. By Value

9.3.3.2. Market Share & Forecast

9.3.3.2.1. By Dosage Form

9.3.3.2.2. By Route of Administration

9.3.3.2.3. By Patient Age

9.3.3.2.4. By Application

9.3.3.2.5. By Distribution Channel

10. South America Remdesivir Market Outlook

10.1. Market Size & Forecast

10.1.1. By Value

10.2. Market Share & Forecast

10.2.1. By Dosage Form

10.2.2. By Route of Administration

10.2.3. By Patient Age

10.2.4. By Application

10.2.5. By Distribution Channel

10.2.6. By Country

10.3. South America: Country Analysis

10.3.1. Brazil Remdesivir Market Outlook

10.3.1.1. Market Size & Forecast

10.3.1.1.1. By Value

10.3.1.2. Market Share & Forecast

10.3.1.2.1. By Dosage Form

10.3.1.2.2. By Route of Administration

10.3.1.2.3. By Patient Age

10.3.1.2.4. By Application

10.3.1.2.5. By Distribution Channel

10.3.2. Colombia Remdesivir Market Outlook

10.3.2.1. Market Size & Forecast

10.3.2.1.1. By Value

10.3.2.2. Market Share & Forecast

10.3.2.2.1. By Dosage Form

10.3.2.2.2. By Route of Administration

10.3.2.2.3. By Patient Age

10.3.2.2.4. By Application

10.3.2.2.5. By Distribution Channel

10.3.3. Argentina Remdesivir Market Outlook

10.3.3.1. Market Size & Forecast

10.3.3.1.1. By Value

10.3.3.2. Market Share & Forecast

10.3.3.2.1. By Dosage Form

10.3.3.2.2. By Route of Administration

10.3.3.2.3. By Patient Age

10.3.3.2.4. By Application

10.3.3.2.5. By Distribution Channel

11. Market Dynamics

11.1. Drivers

11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)

12.2. Product Launches (If Any)

12.3. Recent Developments

13. Global Remdesivir Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry

14.2. Potential of New Entrants

14.3. Power of Suppliers

14.4. Power of Customers

14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Gilead Sciences, Inc.

15.1.1. Business Overview

15.1.2. Products & Services

15.1.3. Recent Developments

15.1.4. Key Personnel

15.1.5. SWOT Analysis

15.2. Cipla Limited

15.3. Dr. Reddy’s Laboratories Limited

15.4. Hetero Labs Limited

15.5. Mylan N.V.

15.6. Sun Pharmaceutical Industries Limited

15.7. Zydus Lifesciences Limited

15.8. Jubilant Pharmova Limited

15.9. Aurobindo Pharma Limited

15.10. Fujifilm Toyama Chemical Co., Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer

Figures and Tables

Figure 1: Global Remdesivir Market Size, By Value (USD Million), 2020-2026F

Figure 2: Global Remdesivir Market Share, By Dosage Form, By Value, 2020-2026F

Figure 3: Global Remdesivir Market Share, By Route of Administration, By Value, 2020-2026F

Figure 4: Global Remdesivir Market Share, By Patient Age, By Value, 2020-2026F

Figure 5: Global Remdesivir Market Share, By Application, By Value, 2020-2026F

Figure 6: Global Remdesivir Market Share, By Distribution Channel, By Value, 2020-2026F

Figure 7: Global Remdesivir Market Share, By Company, By Value, 2020

Figure 8: Global Remdesivir Market Share, By Region, By Value, 2020-2026F

Figure 9: Global Remdesivir Product Market Map, By Value, 2020-2026F

Figure 10: North America Remdesivir Market Size, By Value (USD Million), 2020-2026F

Figure 11: North America Remdesivir Market Share, By Dosage Form, By Value, 2020-2026F

Figure 12: North America Remdesivir Market Share, By Route of Administration, By Value, 2020-2026F

Figure 13: North America Remdesivir Market Share, By Patient Age, By Value, 2020-2026F

Figure 14: North America Remdesivir Market Share, By Application, By Value, 2020-2026F

Figure 15: North America Remdesivir Market Share, By Distribution Channel, By Value, 2020-2026F

Figure 16: North America Remdesivir Market Share, By Country, By Value, 2020-2026F

Figure 17: United States Remdesivir Market Size, By Value (USD Million), 2020-2026F

Figure 18: United States Remdesivir Market Share, By Dosage Form, By Value, 2020-2026F

Figure 19: United States Remdesivir Market Share, By Route of Administration, By Value, 2020-2026F

Figure 20: United States Remdesivir Market Share, By Patient Age, By Value, 2020-2026F

Figure 21: United States Remdesivir Market Share, By Application, By Value, 2020-2026F

Figure 22: United States Remdesivir Market Share, By Distribution Channel, By Value, 2020-2026F

Figure 23: Mexico Remdesivir Market Size, By Value (USD Million), 2020-2026F

Figure 24: Mexico Remdesivir Market Share, By Dosage Form, By Value, 2020-2026F

Figure 25: Mexico Remdesivir Market Share, By Route of Administration, By Value, 2020-2026F

Figure 26: Mexico Remdesivir Market Share, By Patient Age, By Value, 2020-2026F

Figure 27: Mexico Remdesivir Market Share, By Application, By Value, 2020-2026F

Figure 28: Mexico Remdesivir Market Share, By Distribution Channel, By Value, 2020-2026F

Figure 29: Canada Remdesivir Market Size, By Value (USD Million), 2020-2026F

Figure 30: Canada Remdesivir Market Share, By Dosage Form, By Value, 2020-2026F

Figure 31: Canada Remdesivir Market Share, By Route of Administration, By Value, 2020-2026F

Figure 32: Canada Remdesivir Market Share, By Patient Age, By Value, 2020-2026F

Figure 33: Canada Remdesivir Market Share, By Application, By Value, 2020-2026F

Figure 34: Canada Remdesivir Market Share, By Distribution Channel, By Value, 2020-2026F

Figure 35: Asia-Pacific Remdesivir Market Size, By Value (USD Million), 2020-2026F

Figure 36: Asia-Pacific Remdesivir Market Share, By Dosage Form, By Value, 2020-2026F

Figure 37: Asia-Pacific Remdesivir Market Share, By Route of Administration, By Value, 2020-2026F

Figure 38: Asia-Pacific Remdesivir Market Share, By Patient Age, By Value, 2020-2026F

Figure 39: Asia-Pacific Remdesivir Market Share, By Application, By Value, 2020-2026F

Figure 40: Asia-Pacific Remdesivir Market Share, By Distribution Channel, By Value, 2020-2026F

Figure 41: Asia-Pacific Remdesivir Market Share, By Country, By Value, 2020-2026F

Figure 42: India Remdesivir Market Size, By Value (USD Million), 2020-2026F

Figure 43: India Remdesivir Market Share, By Dosage Form, By Value, 2020-2026F

Figure 44: India Remdesivir Market Share, By Route of Administration, By Value, 2020-2026F

Figure 45: India Remdesivir Market Share, By Patient Age, By Value, 2020-2026F

Figure 46: India Remdesivir Market Share, By Application, By Value, 2020-2026F

Figure 47: India Remdesivir Market Share, By Distribution Channel, By Value, 2020-2026F

Figure 48: Japan Remdesivir Market Size, By Value (USD Million), 2020-2026F

Figure 49: Japan Remdesivir Market Share, By Dosage Form, By Value, 2020-2026F

Figure 50: Japan Remdesivir Market Share, By Route of Administration, By Value, 2020-2026F

Figure 51: Japan Remdesivir Market Share, By Patient Age, By Value, 2020-2026F

Figure 52: Japan Remdesivir Market Share, By Application, By Value, 2020-2026F

Figure 53: Japan Remdesivir Market Share, By Distribution Channel, By Value, 2020-2026F

Figure 54: China Remdesivir Market Size, By Value (USD Million), 2020-2026F

Figure 55: China Remdesivir Market Share, By Dosage Form, By Value, 2020-2026F

Figure 56: China Remdesivir Market Share, By Route of Administration, By Value, 2020-2026F

Figure 57: China Remdesivir Market Share, By Patient Age, By Value, 2020-2026F

Figure 58: China Remdesivir Market Share, By Application, By Value, 2020-2026F

Figure 59: China Remdesivir Market Share, By Distribution Channel, By Value, 2020-2026F

Figure 60: South Korea Remdesivir Market Size, By Value (USD Million), 2020-2026F

Figure 61: South Korea Remdesivir Market Share, By Dosage Form, By Value, 2020-2026F

Figure 62: South Korea Remdesivir Market Share, By Route of Administration, By Value, 2020-2026F

Figure 63: South Korea Remdesivir Market Share, By Patient Age, By Value, 2020-2026F

Figure 64: South Korea Remdesivir Market Share, By Application, By Value, 2020-2026F

Figure 65: South Korea Remdesivir Market Share, By Distribution Channel, By Value, 2020-2026F

Figure 66: Australia Remdesivir Market Size, By Value (USD Million), 2020-2026F

Figure 67: Australia Remdesivir Market Share, By Dosage Form, By Value, 2020-2026F

Figure 68: Australia Remdesivir Market Share, By Route of Administration, By Value, 2020-2026F

Figure 69: Australia Remdesivir Market Share, By Patient Age, By Value, 2020-2026F

Figure 70: Australia Remdesivir Market Share, By Application, By Value, 2020-2026F

Figure 71: Australia Remdesivir Market Share, By Distribution Channel, By Value, 2020-2026F

Figure 72: Europe Remdesivir Market Size, By Value (USD Million), 2020-2026F

Figure 73: Europe Remdesivir Market Share, By Dosage Form, By Value, 2020-2026F

Figure 74: Europe Remdesivir Market Share, By Route of Administration, By Value, 2020-2026F

Figure 75: Europe Remdesivir Market Share, By Patient Age, By Value, 2020-2026F

Figure 76: Europe Remdesivir Market Share, By Application, By Value, 2020-2026F

Figure 77: Europe Remdesivir Market Share, By Distribution Channel, By Value, 2020-2026F

Figure 78: Europe Remdesivir Market Share, By Country, By Value, 2020-2026F

Figure 79: France Remdesivir Market Size, By Value (USD Million), 2020-2026F

Figure 80: France Remdesivir Market Share, By Dosage Form, By Value, 2020-2026F

Figure 81: France Remdesivir Market Share, By Route of Administration, By Value, 2020-2026F

Figure 82: France Remdesivir Market Share, By Patient Age, By Value, 2020-2026F

Figure 83: France Remdesivir Market Share, By Application, By Value, 2020-2026F

Figure 84: France Remdesivir Market Share, By Distribution Channel, By Value, 2020-2026F

Figure 85: United Kingdom Remdesivir Market Size, By Value (USD Million), 2020-2026F

Figure 86: United Kingdom Remdesivir Market Share, By Dosage Form, By Value, 2020-2026F

Figure 87: United Kingdom Remdesivir Market Share, By Route of Administration, By Value, 2020-2026F

Figure 88: United Kingdom Remdesivir Market Share, By Patient Age, By Value, 2020-2026F

Figure 89: United Kingdom Remdesivir Market Share, By Application, By Value, 2020-2026F

Figure 90: United Kingdom Remdesivir Market Share, By Distribution Channel, By Value, 2020-2026F

Figure 91: Italy Remdesivir Market Size, By Value (USD Million), 2020-2026F

Figure 92: Italy Remdesivir Market Share, By Dosage Form, By Value, 2020-2026F

Figure 93: Italy Remdesivir Market Share, By Route of Administration, By Value, 2020-2026F

Figure 94: Italy Remdesivir Market Share, By Patient Age, By Value, 2020-2026F

Figure 95: Italy Remdesivir Market Share, By Application, By Value, 2020-2026F

Figure 96: Italy Remdesivir Market Share, By Distribution Channel, By Value, 2020-2026F

Figure 97: Germany Remdesivir Market Size, By Value (USD Million), 2020-2026F

Figure 98: Germany Remdesivir Market Share, By Dosage Form, By Value, 2020-2026F

Figure 99: Germany Remdesivir Market Share, By Route of Administration, By Value, 2020-2026F

Figure 100: Germany Remdesivir Market Share, By Patient Age, By Value, 2020-2026F

Figure 101: Germany Remdesivir Market Share, By Application, By Value, 2020-2026F

Figure 102: Germany Remdesivir Market Share, By Distribution Channel, By Value, 2020-2026F

Figure 103: Spain Remdesivir Market Size, By Value (USD Million), 2020-2026F

Figure 104: Spain Remdesivir Market Share, By Dosage Form, By Value, 2020-2026F

Figure 105: Spain Remdesivir Market Share, By Route of Administration, By Value, 2020-2026F

Figure 106: Spain Remdesivir Market Share, By Patient Age, By Value, 2020-2026F

Figure 107: Spain Remdesivir Market Share, By Application, By Value, 2020-2026F

Figure 108: Spain Remdesivir Market Share, By Distribution Channel, By Value, 2020-2026F

Figure 109: South America Remdesivir Market Size, By Value (USD Million), 2020-2026F

Figure 110: South America Remdesivir Market Share, By Dosage Form, By Value, 2020-2026F

Figure 111: South America Remdesivir Market Share, By Route of Administration, By Value, 2020-2026F

Figure 112: South America Remdesivir Market Share, By Patient Age, By Value, 2020-2026F

Figure 113: South America Remdesivir Market Share, By Application, By Value, 2020-2026F

Figure 114: South America Remdesivir Market Share, By Distribution Channel, By Value, 2020-2026F

Figure 115: South America Remdesivir Market Share, By Country, By Value, 2020-2026F

Figure 116: Brazil Remdesivir Market Size, By Value (USD Million), 2020-2026F

Figure 117: Brazil Remdesivir Market Share, By Dosage Form, By Value, 2020-2026F

Figure 118: Brazil Remdesivir Market Share, By Route of Administration, By Value, 2020-2026F

Figure 119: Brazil Remdesivir Market Share, By Patient Age, By Value, 2020-2026F

Figure 120: Brazil Remdesivir Market Share, By Application, By Value, 2020-2026F

Figure 121: Brazil Remdesivir Market Share, By Distribution Channel, By Value, 2020-2026F

Figure 122: Argentina Remdesivir Market Size, By Value (USD Million), 2020-2026F

Figure 123: Argentina Remdesivir Market Share, By Dosage Form, By Value, 2020-2026F

Figure 124: Argentina Remdesivir Market Share, By Route of Administration, By Value, 2020-2026F

Figure 125: Argentina Remdesivir Market Share, By Patient Age, By Value, 2020-2026F

Figure 126: Argentina Remdesivir Market Share, By Application, By Value, 2020-2026F

Figure 127: Argentina Remdesivir Market Share, By Distribution Channel, By Value, 2020-2026F

Figure 128: Colombia Remdesivir Market Size, By Value (USD Million), 2020-2026F

Figure 129: Colombia Remdesivir Market Share, By Dosage Form, By Value, 2020-2026F

Figure 130: Colombia Remdesivir Market Share, By Route of Administration, By Value, 2020-2026F

Figure 131: Colombia Remdesivir Market Share, By Patient Age, By Value, 2020-2026F

Figure 132: Colombia Remdesivir Market Share, By Application, By Value, 2020-2026F

Figure 133: Colombia Remdesivir Market Share, By Distribution Channel, By Value, 2020-2026F

Figure 134: Middle East and Africa Remdesivir Market Size, By Value (USD Million), 2020-2026F

Figure 135: Middle East and Africa Remdesivir Market Share, By Dosage Form, By Value, 2020-2026F

Figure 136: Middle East and Africa Remdesivir Market Share, By Route of Administration, By Value, 2020-2026F

Figure 137: Middle East and Africa Remdesivir Market Share, By Patient Age, By Value, 2020-2026F

Figure 138: Middle East and Africa Remdesivir Market Share, By Application, By Value, 2020-2026F

Figure 139: Middle East and Africa Remdesivir Market Share, By Distribution Channel, By Value, 2020-2026F

Figure 140: Middle East and Africa Remdesivir Market Share, By Country, By Value, 2020-2026F

Figure 141: Iran Remdesivir Market Size, By Value (USD Million), 2020-2026F

Figure 142: Iran Remdesivir Market Share, By Dosage Form, By Value, 2020-2026F

Figure 143: Iran Remdesivir Market Share, By Route of Administration, By Value, 2020-2026F

Figure 144: Iran Remdesivir Market Share, By Patient Age, By Value, 2020-2026F

Figure 145: Iran Remdesivir Market Share, By Application, By Value, 2020-2026F

Figure 146: Iran Remdesivir Market Share, By Distribution Channel, By Value, 2020-2026F

Figure 147: South Africa Remdesivir Market Size, By Value (USD Million), 2020-2026F

Figure 148: South Africa Remdesivir Market Share, By Dosage Form, By Value, 2020-2026F

Figure 149: South Africa Remdesivir Market Share, By Route of Administration, By Value, 2020-2026F

Figure 150: South Africa Remdesivir Market Share, By Patient Age, By Value, 2020-2026F

Figure 151: South Africa Remdesivir Market Share, By Application, By Value, 2020-2026F

Figure 152: South Africa Remdesivir Market Share, By Distribution Channel, By Value, 2020-2026F

Figure 153: UAE Remdesivir Market Size, By Value (USD Million), 2020-2026F

Figure 154: UAE Remdesivir Market Share, By Dosage Form, By Value, 2020-2026F

Figure 155: UAE Remdesivir Market Share, By Route of Administration, By Value, 2020-2026F

Figure 156: UAE Remdesivir Market Share, By Patient Age, By Value, 2020-2026F

Figure 157: UAE Remdesivir Market Share, By Application, By Value, 2020-2026F

Figure 158: UAE Remdesivir Market Share, By Distribution Channel, By Value, 2020-2026F

Figure 159: Saudi Arabia Remdesivir Market Size, By Value (USD Million), 2020-2026F

Figure 160: Saudi Arabia Remdesivir Market Share, By Dosage Form, By Value, 2020-2026F

Figure 161: Saudi Arabia Remdesivir Market Share, By Route of Administration, By Value, 2020-2026F

Figure 162: Saudi Arabia Remdesivir Market Share, By Patient Age, By Value, 2020-2026F

Figure 163: Saudi Arabia Remdesivir Market Share, By Application, By Value, 2020-2026F

Figure 164: Saudi Arabia Remdesivir Market Share, By Distribution Channel, By Value, 2020-2026F

Figure 165: Kuwait Remdesivir Market Size, By Value (USD Million), 2020-2026F

Figure 166: Kuwait Remdesivir Market Share, By Dosage Form, By Value, 2020-2026F

Figure 167: Kuwait Remdesivir Market Share, By Route of Administration, By Value, 2020-2026F

Figure 168: Kuwait Remdesivir Market Share, By Patient Age, By Value, 2020-2026F

Figure 169: Kuwait Remdesivir Market Share, By Application, By Value, 2020-2026F

Figure 170: Kuwait Remdesivir Market Share, By Distribution Channel, By Value, 2020-2026F

Report Description

Table of content

Figures and Tables

Frequently asked questions

What was the market size of the Global Remdesivir Market in 2025?

Which is the dominating region in the Global Remdesivir Market?

Which is the fastest growing segment in the Global Remdesivir Market?

What is the expected growth rate of the Global Remdesivir Market?